Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FSCN1 | Q16658 | 6/20 | 0.52 |
| ▸ | KEAP1 | Q14145 | 6/20 | 0.52 |
| ▸ | NFE2L2 | Q16236 | 6/20 | 0.52 |
| ▸ | MEN1 | O00255 | 5/20 | 0.47 |
| ▸ | BLM | P54132 | 5/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.47 |
| ▸ | POLB | P06746 | 4/20 | 0.47 |
| ▸ | G6PD | P11413 | 3/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.47 |
| ▸ | TDP2 | O95551 | 1/20 | 0.47 |
| ▸ | CFTR | P13569 | 1/20 | 0.47 |
| ▸ | GOPC | Q9HD26 | 1/20 | 0.47 |
| ▸ | MCL1 | Q07820 | 6/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.46 |
| ▸ | MAPT | P10636 | 4/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.46 |
| ▸ | THRB | P10828 | 3/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.46 |
| ▸ | HKDC1 | Q2TB90 | 3/20 | 0.46 |
| ▸ | GAA | P10253 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13510224 | 0.90 | ABL1 (0.51) | FSCN1KEAP1NFE2L2MEN1BLM | |
| SCHEMBL13510275 | 0.86 | BRAF (0.49) | FSCN1KEAP1NFE2L2MEN1BLM | |
| SCHEMBL13510213 | 0.85 | BRAF (0.52) | FSCN1KEAP1NFE2L2MEN1BLM | |
| SCHEMBL13509748 | 0.85 | STAT3 (0.59) | FSCN1KEAP1NFE2L2MEN1BLM | |
| SCHEMBL30723325 | 0.85 | KEAP1 (0.71) | FSCN1KEAP1NFE2L2MEN1BLM | |
| SCHEMBL15521849 | 0.85 | KEAP1 (0.71) | FSCN1KEAP1NFE2L2MEN1BLM | |
| SCHEMBL13510186 | 0.85 | BRAF (0.54) | FSCN1KEAP1NFE2L2MEN1BLM | |
| SCHEMBL13510273 | 0.84 | HKDC1 (0.50) | FSCN1KEAP1NFE2L2MEN1BLM | |
| SCHEMBL13510269 | 0.84 | MCL1 (0.59) | FSCN1KEAP1NFE2L2MEN1BLM | |
| SCHEMBL13510172 | 0.84 | KEAP1 (0.54) | FSCN1KEAP1NFE2L2MEN1BLM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11161831-B2 | Methods and compositions for treatment of muscle wasting, muscle weakness, and/or cachexia | BAYLOR COLLEGE OF MEDICINE (US) | 2021-11-02 | — | — | US | disclosed |
| WO-2021113551-A1 | THERAPEUTIC COMPOUNDS FOR METHODS OF USE IN INSULIN RESISTANCE | BAYLOR COLLEGE OF MEDICINE (US) | 2021-06-10 | — | — | WO | disclosed |
| US-20200331880-A1 | METHODS AND COMPOSITIONS FOR TREATMENT OF MUSCLE WASTING, MUSCLE WEAKNESS, AND/OR CACHEXIA | BAYLOR COLLEGE OF MEDICINE | 2020-10-22 | — | — | US | disclosed |
| US-10676455-B2 | Methods and compositions for treatment of muscle wasting, muscle weakness, and/or cachexia | BAYLOR COLLEGE OF MEDICINE (US) | 2020-06-09 | — | — | US | disclosed |
| US-20150051233-A1 | METHODS AND COMPOSITIONS FOR TREATMENT OF FIBROSIS | BAYLOR COLLEGE OF MEDICINE | 2015-02-19 | — | — | US | disclosed |
| US-20150051233-A1 | METHODS AND COMPOSITIONS FOR TREATMENT OF FIBROSIS | BAYLOR COLLEGE OF MEDICINE | 2015-02-19 | — | — | US | disclosed |
| US-20150031714-A1 | METHODS AND COMPOSITIONS FOR PREVENTION OF ALLERGIC REACTION | BAYLOR COLLEGE OF MEDICINE | 2015-01-29 | — | — | US | disclosed |
| US-20150024032-A1 | METHODS AND COMPOSITIONS FOR TREATMENT OF MUSCLE WASTING, MUSCLE WEAKNESS, AND/OR CACHEXIA | BAYLOR COLLEGE OF MEDICINE | 2015-01-22 | — | — | US | disclosed |
| US-20150024032-A1 | METHODS AND COMPOSITIONS FOR TREATMENT OF MUSCLE WASTING, MUSCLE WEAKNESS, AND/OR CACHEXIA | BAYLOR COLLEGE OF MEDICINE | 2015-01-22 | — | — | US | disclosed |
| US-20140296270-A1 | STAT3 Inhibitors | BAYLOR COLLEGE OF MEDICINE (US) | 2014-10-02 | — | — | US | disclosed |
| US-20140296270-A1 | STAT3 Inhibitors | BAYLOR COLLEGE OF MEDICINE (US) | 2014-10-02 | — | — | US | disclosed |
| US-8779001-B2 | Stat3 inhibitors | The United States of America National Institute of Health (NIH) (US) | 2014-07-15 | — | — | US | disclosed |
| US-8779001-B2 | Stat3 inhibitors | The United States of America National Institute of Health (NIH) (US) | 2014-07-15 | — | — | US | disclosed |
| US-20110312984-A1 | STAT3 INHIBITORS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2011-12-22 | — | — | US | disclosed |
| US-20100041685-A1 | STAT3 INHIBITORS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2010-02-18 | — | — | US | disclosed |
| US-20100041685-A1 | STAT3 INHIBITORS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2010-02-18 | — | — | US | disclosed |
| WO-2009149192-A1 | STAT3 INHIBITORS | BAYLOR COLLEGE OF MEDICINE (US) | 2009-12-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150051233-A1 | METHODS AND COMPOSITIONS FOR TREATMENT OF FIBROSIS | STAT3, MMP1, MMP8 | FSCN1 1689/4885KEAP1 500/4885NFE2L2 441/4885 |
| US-10676455-B2 | Methods and compositions for treatment of muscle wasting, muscle weakness, and/or cachexia | PYGM, MYLK2, STAT3 | FSCN1 2788/4885KEAP1 1375/4885NFE2L2 885/4885 |
| US-11161831-B2 | Methods and compositions for treatment of muscle wasting, muscle weakness, and/or cachexia | PYGM, MYLK2, STAT3 | FSCN1 2788/4885KEAP1 1375/4885NFE2L2 885/4885 |
| US-20150024032-A1 | METHODS AND COMPOSITIONS FOR TREATMENT OF MUSCLE WASTING, MUSCLE WEAKNESS, AND/OR CACHEXIA | PYGM, MYLK2, STAT3 | FSCN1 2788/4885KEAP1 1375/4885NFE2L2 885/4885 |
| US-20100041685-A1 | STAT3 INHIBITORS | STAT3, STAT1, JAK2 | FSCN1 4052/4885KEAP1 2561/4885NFE2L2 956/4885 |
| US-20200331880-A1 | METHODS AND COMPOSITIONS FOR TREATMENT OF MUSCLE WASTING, MUSCLE WEAKNESS, AND/OR CACHEXIA | PYGM, MYLK2, STAT3 | FSCN1 2788/4885KEAP1 1375/4885NFE2L2 885/4885 |
| US-20140296270-A1 | STAT3 Inhibitors | STAT3, STAT1, JAK2 | FSCN1 4052/4885KEAP1 2561/4885NFE2L2 956/4885 |
| US-20150031714-A1 | METHODS AND COMPOSITIONS FOR PREVENTION OF ALLERGIC REACTION | JAK2, STAT3, STAT6 | FSCN1 4799/4885KEAP1 81/4885NFE2L2 194/4885 |
| US-20110312984-A1 | STAT3 INHIBITORS | STAT3, STAT1, JAK2 | FSCN1 4052/4885KEAP1 2561/4885NFE2L2 956/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.